Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Blueprint Medicines (BPMC) Misses Q4 EPS by 5c
March 11, 2016 8:10 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.58), $0.05 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.85 million.
As of December 31, 2015, cash and cash equivalents were $162.7 million, as compared to $47.2 million as of... More
